Net sales of the company rose to Rs. 634.22 crore for the third quarter, as against Rs. 516.59 crore during the same period of 2011-12 fiscal.
"We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in ROW (rest of the world) markets which now accounts for a significant part of our business," Biocon chairman and managing director Kiran Mazumdar-Shaw said in a statement.
Shares of Biocon were trading at Rs. 266 on the BSE in the afternoon trade, up 0.89% from its previous close.